FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

There are several options available to help patients with anemia and neutropenia. Treatments can range from simple rest and careful monitoring, to medications or infusions of biological agents (growth ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A retrospective study of patients diagnosed with any malignant ...

A new study helps dispel mounting confusion over the safety of blockbuster anemia drugs -- erythropoiesis-stimulating agents -- for people with kidney disease requiring dialysis, as federal regulators ...

Experts offered pointers on appropriate use of iron therapies, erythropoiesis stimulating agents (ESAs), and hypoxia inducible factor inhibitors (HIF-PHI) for anemia of chronic kidney disease (CKD).

On January 1, 2021, new evaluation and management (E&M) coding guidelines for clinical office visits go into effect across the US. These guidelines, which reflect the most significant change in E&M ...

The new NCCN Guidelines for Patients outline the causes of anemia and neutropenia as well as warning signs and potential management options that patients and caregivers can discuss with physicians.

RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO ...

The National Comprehensive Cancer Network ® (NCCN ®) announced today the publication of new NCCN Guidelines for Patients ®: Anemia and Neutropenia, Low Red and White Blood Cell Counts funded by the ...